ERBB2 and neoplasm: Whether “polysomy” 17 drives HER2 amplification or the opposite is true, as was recently suggested [54,73], remains unanswered; it is, however, noteworthy that “polysomy” 17 is rarely observed in circulating tumor cells from patients with metastatic breast cancer and when present, it corresponds to HER2-negative primary tumors [74].